Anemia and cardiovascular disease in diabetic nephropathy
- PMID: 16898574
- DOI: 10.1007/s11892-006-0037-4
Anemia and cardiovascular disease in diabetic nephropathy
Abstract
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in people with diabetes and in those with chronic kidney disease (CKD). Diabetes, occurring in epidemic proportions in the United States and worldwide, is also the leading cause of CKD and kidney failure. Identification of modifiable risk factors for CVD in patients with diabetes and CKD is thus of paramount importance. Anemia is increasingly recognized as a potential CVD risk factor in patients with diabetic nephropathy, in whom it is generally more severe and occurs at an earlier stage of CKD. In this review, we discuss the epidemiologic evidence, pathophysiologic mechanisms, and the current research findings, highlighting the role of anemia as a potential modifiable risk factor for CVD in patients with diabetic nephropathy, a particularly vulnerable population for CVD.
Similar articles
-
Cardiovascular disease in patients with diabetic nephropathy.Curr Mol Med. 2008 Sep;8(6):533-43. doi: 10.2174/156652408785747960. Curr Mol Med. 2008. PMID: 18781960 Review.
-
Erythropoietic stress and anemia in diabetes mellitus.Nat Rev Endocrinol. 2009 Apr;5(4):204-10. doi: 10.1038/nrendo.2009.17. Nat Rev Endocrinol. 2009. PMID: 19352318 Review.
-
Statin use in patients with diabetes and kidney disease: the Japanese experience.J Atheroscler Thromb. 2013;20(5):407-24. doi: 10.5551/jat.16261. Epub 2013 Mar 22. J Atheroscler Thromb. 2013. PMID: 23518468 Review.
-
The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment.Rev Cardiovasc Med. 2005 Winter;6(1):1-10. Rev Cardiovasc Med. 2005. PMID: 15741920 Review.
-
Anemia with impaired erythropoietin response in diabetic patients.Arch Intern Med. 2005 Feb 28;165(4):466-9. doi: 10.1001/archinte.165.4.466. Arch Intern Med. 2005. PMID: 15738380
Cited by
-
Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.Curr Diab Rep. 2010 Apr;10(2):87-9. doi: 10.1007/s11892-010-0098-2. Curr Diab Rep. 2010. PMID: 20425565 No abstract available.
-
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease.Patient Prefer Adherence. 2008 Feb 2;2:195-200. doi: 10.2147/ppa.s2356. Patient Prefer Adherence. 2008. PMID: 19920963 Free PMC article.
-
Management of anemia in patients with diabetic kidney disease: A consensus statement.Indian J Endocrinol Metab. 2016 Mar-Apr;20(2):268-81. doi: 10.4103/2230-8210.176348. Indian J Endocrinol Metab. 2016. PMID: 27042425 Free PMC article. Review.
-
Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data.BMC Nephrol. 2020 Mar 7;21(1):88. doi: 10.1186/s12882-020-01746-4. BMC Nephrol. 2020. PMID: 32143582 Free PMC article.
-
Associations between hemoglobin concentrations and the clinical characteristics of patients with type 2 diabetes.Korean J Intern Med. 2012 Sep;27(3):285-92. doi: 10.3904/kjim.2012.27.3.285. Epub 2012 Sep 1. Korean J Intern Med. 2012. PMID: 23019393 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical